arrow
J

Jonathan Rios-Doria

AstraZeneca
H指数:15
被引数:1,320

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

INCA33890, a novel PD-1xTGF.R2 bispecific antibody conditionally antagonizes TGFβ signaling in primary immune cells co- expressing PD-
2023-04-041
PRE
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
2022-03-0768
OAAI
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
2020-12-0734
OAAI
Characterization of INCB081776, a potent and selective dual AXL/MER kinase inhibitor
2018-07-0112
PRE
Antibody-drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads alter the tumor immune microenvironment and synergize with multiple immunotherapies
2017-07-011
PRE
Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies

带有吡咯并苯并二氮杂或微管溶素有效载荷的抗体-药物结合物具有免疫调节作用,并与多种免疫疗法协同作用

2017-05-1484
OAAI
Targeting CD73 in the tumor microenvironment with MEDI9447
2016-07-11247
OAAI
Medi3622, a monoclonal antibody to ADAM17, inhibits tumor growth by inhibiting EGFR- and non-EGFR-mediated pathways
2015-08-010
PRE
A Monoclonal Antibody to ADAM17 Inhibits Tumor Growth by Inhibiting EGFR and Non-EGFR-Mediated Pathways
2015-07-0647
OAAI